In this study, the investigators will investigate and characterize acute medical patients in order to optimize patient courses in the acute care departments, especially with regard to polypharmacy and undernourishment. In addition, the investigators will investigate underlying immunological mechanisms of chronic inflammation and biological aging in this population to improve the current knowledge and possibilities for preventing chronic diseases and acute hospitalization.
Malnutrition: Malnutrition among elderly is associated with frailty, including loss of weight, muscle mass, function and quality of life and also with an increased number of hospital admissions. In this study, the investigators aim to describe the development of and the risk factors for malnutrition from admission to 4 weeks after discharge, in addition the investigators wish to characterize the inflammatory state of the malnourished patients. Inappropriate polypharmacy: The broad variation among elderly in health, number of chronic diseases, organ function, biological age and function makes the prescription of drugs to this population a very complex task with a high risk of inappropriate medication. 5-30% of all non-elective admissions are caused by inappropriate medications, and many of these are preventable. Therefore, the investigators aim to investigate the feasibility of a pharmacist-geriatrician medication review in the acute care department and the effect on the Medication Appropriateness Index score (MAI-score) . Chronic inflammation and biological aging: Chronic inflammation and biological aging promote the development of age-related chronic diseases. There is a large variation in the rate of aging between individuals, in particular among the elderly. This means that the chronological age of a person often does not reflect its true state of aging, the biological age. This challenges the ability to provide appropriate care and to predict responses to treatment and interventions in elderly patients. The underlying causes and mechanisms of biological aging and chronic inflammation are not well understood. There are currently no validated methods for measuring biological age and no measures of chronic inflammation which can be used in an acute setting. Here, the investigators aim to test a novel model for chronic inflammation and investigate the role of the NLRP3 inflammasome, NFkB (nuclear factor kappa light chain enhancer of activated B cells) and miRNAs in biological aging and chronic inflammation. The study is prospective with 3 groups of study participants: one group is included in the Acute Medical Department and two healthy control groups (one young and one older). The follow-up comprises two predefined examinations and any readmissions at our hospital. Furthermore, participants are followed in the national registries.
Study Type
OBSERVATIONAL
Enrollment
212
Amager & Hvidovre Hospital
Hvidovre, Capital Region, Denmark
Eating validation scheme score
Development in nutritional status and risk factors of malnutrition within the FAM group.
Time frame: From inclusion to 4 weeks after discharge
MAI score (Medication Appropriateness Index)
Difference in summed MAI-score per patient. MAI score between inclusion and first follow-up visit (FAM group)
Time frame: From inclusion to 4 weeks after discharge
NF-kB (Nuclear Factor Kappa light chain enhancer og activated B cells) activity
The development in NF-kB activity between the groups will be investigated. The association of NF-kB activity with biological ageing-measured by chronic inflammation, and loss of function and cognition-will also be investigated.
Time frame: From inclusion to 56 weeks after discharge
Chronic inflammation
Stability and discriminative ability of new model for chronic inflammation (Control group 2)
Time frame: From inclusion to 4 weeks after inclusion
NLRP3 activity
Difference in NLRP3 inflammasome activity between groups.
Time frame: From inclusion to 56 weeks after discharge
Bodyweight (kg)
Development in bodyweight
Time frame: From inclusion to 4 and 56 weeks after discharge
Quality of life
EQ-5D-5L(EuroQol-5Dimentions-5Llevels), mini geriatric depression score
Time frame: From inclusion to 56 weeks after discharge
Medication under-prescribing
Assessment of underutilization Index (AOU)
Time frame: From inclusion to 4 weeks after discharge
Inflammation in malnourished patients
Characterize the level of inflammation in malnourished patients
Time frame: 4 weeks after discharge
Functional recovery score
Assessing activities of daily living to characterize development in physical performance
Time frame: From inclusion to 56 weeks after discharge
Cystatin C
Time frame: From inclusion to 56 weeks after discharge
Cytokine concentrations
The concentration of cytokines at baseline and in response to stimulation will be measured
Time frame: From inclusion to 56 weeks after discharge
Cytometry
Characterization of immune cell subsets
Time frame: From inclusion to 56 weeks after discharge
miRNA
Levels of miRNA will be measured, and their association with NF-kB activity and biological ageing will be investigated.
Time frame: From inclusion to 56 weeks after discharge
NF-kB activation
The activation of NF-kB in response to stimulation.
Time frame: From inclusion to 56 weeks after discharge
C-reactive protein (inflammation)
Difference in inflammation between groups
Time frame: From inclusion to 56 weeks after discharge
Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml)
The plasma level of suPAR is a measure of inflammation and can be used to assess the difference in inflammation between groups
Time frame: From inclusion to 56 weeks after discharge
Frequency of physicians' acceptance of suggested changes in medications
Time frame: At inclusion and at 4 weeks after discharge in the FAM group
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.